Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C45M | ISIN: US7473241013 | Ticker-Symbol:
NASDAQ
31.03.25
21:24 Uhr
0,980 US-Dollar
-0,085
-7,97 %
1-Jahres-Chart
PYXIS ONCOLOGY INC Chart 1 Jahr
5-Tage-Chart
PYXIS ONCOLOGY INC 5-Tage-Chart

Aktuelle News zur PYXIS ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiPyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 20251
19.03.Pyxis Oncology GAAP EPS of -$1.32 misses by $1.021
18.03.Jefferies cuts Pyxis Oncology target to $6, maintains Buy1
18.03.Pyxis Oncology, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
18.03.Pyxis Oncology, Inc. - 10-K, Annual Report-
18.03.Pyxis Oncology, Inc. Loss At -$77.33 Mln In Full Year-
18.03.Pyxis Oncology, Inc. - 8-K, Current Report-
PYXIS ONCOLOGY Aktie jetzt für 0€ handeln
18.03.Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update135- Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin ("MICVO," formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1...
► Artikel lesen
26.02.FDA fast tracks Pyxis Oncology's head and neck cancer drug3
26.02.Pyxis Oncology rises on FDA fast track tag for lead asset1
26.02.Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer100BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that...
► Artikel lesen
26.02.Pyxis Oncology, Inc. - 8-K, Current Report-
04.02.Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial14
04.02.Pyxis Oncology, Inc. - 8-K, Current Report-
20.12.24Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move15
19.12.24Pyxis Oncology advances lead cancer drug PYX-2015
19.12.24Pyxis Oncology treibt führendes Krebsmedikament PYX-201 voran7
19.12.24Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201328- The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and...
► Artikel lesen
19.12.24Pyxis Oncology, Inc. - 8-K, Current Report-
27.11.24Finanzvorstand von Pyxis Oncology erwirbt Aktien im Wert von 174.364 US-Dollar11
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1